相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) plus bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).
Richard S. Finn et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Radiological response to nivolumab in patients with hepatocellular carcinoma: A multicenter analysis of real-life practice
Jordi Rimola et al.
EUROPEAN JOURNAL OF RADIOLOGY (2021)
Dual Programmed Death Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma
Kohei Shigeta et al.
HEPATOLOGY (2020)
Characterization of auto-immune hepatitis associated with the use of anti-TNFα agents: An analysis of 389 cases in VigiBase
Olivier Vollmer et al.
AUTOIMMUNITY REVIEWS (2020)
Antigen Experienced T Cells from Peripheral Blood Recognize p53 Neoantigens
Parisa Malekzadeh et al.
CLINICAL CANCER RESEARCH (2020)
Nivolumab (NIVO) + ipilimumab (IPI) + cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.
Thomas Yau et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
Richard S. Finn et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma
Bruno Sangro et al.
JOURNAL OF HEPATOLOGY (2020)
Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma
Liang-qing Dong et al.
JOURNAL OF HEPATOLOGY (2020)
Immunological impact of cell death signaling driven by radiation on the tumor microenvironment
Maria Esperanza Rodriguez-Ruiz et al.
NATURE IMMUNOLOGY (2020)
Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer A Systematic Review and Meta-analysis
Jianchun Duan et al.
JAMA ONCOLOGY (2020)
Repurposing infectious disease vaccines for intratumoral immunotherapy
Ignacio Melero et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Immune checkpoint signaling and cancer immunotherapy
Xing He et al.
CELL RESEARCH (2020)
Hepatotoxicity From Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation
Thoetchai (Bee) Peeraphatdit et al.
HEPATOLOGY (2020)
Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC).
Robin Kate Kelley et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
A phase Ib study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC).
Andrew X. Zhu et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
CheckMate 459: Long-term (minimum follow-up 33.6 months) survival outcomes with nivolumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma
B. Sangro et al.
ANNALS OF ONCOLOGY (2020)
Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma
Bruno Sangro et al.
JOURNAL OF HEPATOLOGY (2020)
Identification of neoantigen-reactive T cells in hepatocellular carcinoma: implication in adoptive T cell therapy
Enric Vercher et al.
JOURNAL OF HEPATOLOGY (2020)
Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumors
Ivan Marquez-Rodas et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib The CheckMate 040 Randomized Clinical Trial
Thomas Yau et al.
JAMA ONCOLOGY (2020)
Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline
John D. Gordan et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Sintilimab plus bevacizumab biosimilar vs sorafenib as first-line treatment for advanced hepatocellular carcinoma (ORIENT-32)2
Z. Ren et al.
ANNALS OF ONCOLOGY (2020)
VEGF in Signaling and Disease: Beyond Discovery and Development
Rajendra S. Apte et al.
CELL (2019)
Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers
Parisa Malekzadeh et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Short- and long-term effects of transarterial chemoembolization on portal hypertension in patients with hepatocellular carcinoma
Bernhard Scheiner et al.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2019)
Induction of tolerogenic dendritic cells by activated TGF-/Akt/Smad2 signaling in RIG-I-deficient stemness-high human liver cancer cells
Ming Zhong et al.
BMC CANCER (2019)
The Intersection between Tumor Angiogenesis and Immune Suppression
Osama E. Rahma et al.
CLINICAL CANCER RESEARCH (2019)
Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors
Fangjun Chen et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.
Thomas Yau et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination
Linda Hammerich et al.
NATURE MEDICINE (2019)
Restriction of PD-1 function by cis-PD-L1/CD80 interactions is required for optimal T cell responses
Daisuke Sugiura et al.
SCIENCE (2019)
Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics
Jasmine Davda et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma
Lynn G. Feun et al.
CANCER (2019)
Capecitabine in advanced hepatocellular carcinoma: A multicenter experience
Filippo Pelizzaro et al.
DIGESTIVE AND LIVER DISEASE (2019)
STING pathway agonism as a cancer therapeutic
Blake A. Flood et al.
IMMUNOLOGICAL REVIEWS (2019)
Vascular Targets for the Treatment of Portal Hypertension
Ksenia Brusilovskaya et al.
SEMINARS IN LIVER DISEASE (2019)
β-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma
Marina Ruiz de Galarreta et al.
CANCER DISCOVERY (2019)
The TNF Paradox in Cancer Progression and Immunotherapy
Anne Montfort et al.
FRONTIERS IN IMMUNOLOGY (2019)
Pharmacological modulation of nucleic acid sensors - therapeutic potential and persisting obstacles
Claire Vanpouille-Box et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Immune Desertic Landscapes in Hepatocellular Carcinoma Shaped by β-Catenin Activation
Pedro Berraondo et al.
CANCER DISCOVERY (2019)
LBA38_PRCheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)
T Yau et al.
ANNALS OF ONCOLOGY (2019)
LBA39Randomised efficacy and safety results for atezolizumab (Atezo) + bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC)
M Lee et al.
ANNALS OF ONCOLOGY (2019)
325PAssociation between immune-related adverse events and efficacy of immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma
L Wong et al.
ANNALS OF ONCOLOGY (2019)
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
T. A. Chan et al.
ANNALS OF ONCOLOGY (2019)
Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3
Jun Wang et al.
CELL (2019)
Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies
James J. Harding et al.
CLINICAL CANCER RESEARCH (2019)
WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers
Jason J. Luke et al.
CLINICAL CANCER RESEARCH (2019)
Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods
J. Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Ecto-5-nucleotidase (CD73) is a potential target of hepatocellular carcinoma
Shalaimaiti Shali et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2019)
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
Derin B. Keskin et al.
NATURE (2019)
Intratumoral G100, a TLR4 Agonist, Induces Antitumor Immune Responses and Tumor Regression in Patients with Merkel Cell Carcinoma
Shailender Bhatia et al.
CLINICAL CANCER RESEARCH (2019)
AASLD guidelines for the treatment of hepatocellular carcinoma
Julie K. Heimbach et al.
HEPATOLOGY (2018)
Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients
M. E. Rodriguez-Ruiz et al.
ANNALS OF ONCOLOGY (2018)
Defective HLA class I antigen processing machinery in cancer
Lei Cai et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma
Zachary J. Brown et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Exploring the role of oncolytic viruses in hepatobiliary cancers
Pavan Tenneti et al.
IMMUNOTHERAPY (2018)
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Peter R. Galle et al.
JOURNAL OF HEPATOLOGY (2018)
Bevacizumab Reduces S100A9-Positive MDSCs Linked to Intracranial Control in Patients with EGFR-Mutant Lung Adenocarcinoma
Po-Hao Feng et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo et al.
LANCET (2018)
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2018)
Myeloid-derived suppressor cells coming of age
Filippo Veglia et al.
NATURE IMMUNOLOGY (2018)
A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments
Kevin C. Barry et al.
NATURE MEDICINE (2018)
Liver sinusoidal endothelial cells - gatekeepers of hepatic immunity
Shishir Shetty et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2018)
Chimeric Antigen Receptor Therapy
Carl H. June et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
G. K. Abou-Alfa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Cancer immunotherapy using checkpoint blockade
Antoni Ribas et al.
SCIENCE (2018)
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma
Ferdinandos Skoulidis et al.
CANCER DISCOVERY (2018)
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
A. Vogel et al.
ANNALS OF ONCOLOGY (2018)
Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
Peng Jiang et al.
NATURE MEDICINE (2018)
Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis
Michael Duruisseaux et al.
LANCET RESPIRATORY MEDICINE (2018)
Potentiating cancer vaccine efficacy in liver cancer
Maria Tagliamonte et al.
ONCOIMMUNOLOGY (2018)
Trial Watch: Toll-like receptor agonists in cancer immunotherapy
Melody Smith et al.
ONCOIMMUNOLOGY (2018)
Impact of oncogenic pathways on evasion of antitumour immune responses
Stefani Spranger et al.
NATURE REVIEWS CANCER (2018)
Towards personalized, tumour-specific, therapeutic vaccines for cancer
Zhuting Hu et al.
NATURE REVIEWS IMMUNOLOGY (2018)
Impact of antitumor activity on survival outcomes, and nonconventional benefit, with nivolumab (NIVO) in patients with advanced hepatocellular carcinoma (aHCC): Subanalyses of CheckMate-040.
Anthony B. El-Khoueiry et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Comparison of the Toxicity Profile of PD-1 Versus PD-L1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Analysis of the Literature
Rathi N. Pillai et al.
CANCER (2018)
Liver-infiltrating CD11b(-)CD27(-) NK subsets account for NK-cell dysfunction in patients with hepatocellular carcinoma and are associated with tumor progression
Qiong-Fang Zhang et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2017)
Intratumoral Delivery of Immunotherapy-Act Locally, Think Globally
M. Angela Aznar et al.
JOURNAL OF IMMUNOLOGY (2017)
Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas
Guoying Zhou et al.
GASTROENTEROLOGY (2017)
Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features
Daniela Sia et al.
GASTROENTEROLOGY (2017)
Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update
Masao Omata et al.
HEPATOLOGY INTERNATIONAL (2017)
Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy
Nicole Glodde et al.
IMMUNITY (2017)
LAG3 (CD223) as a cancer immunotherapy target
Lawrence P. Andrews et al.
IMMUNOLOGICAL REVIEWS (2017)
TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action
Wenwen Du et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
Austin G. Duffy et al.
JOURNAL OF HEPATOLOGY (2017)
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix et al.
LANCET (2017)
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry et al.
LANCET (2017)
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
Paolo A. Ascierto et al.
LANCET ONCOLOGY (2017)
A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy
Marta Luksza et al.
NATURE (2017)
Elements of cancer immunity and the cancer-immune set point
Daniel S. Chen et al.
NATURE (2017)
An immunogenic personal neoantigen vaccine for patients with melanoma
Patrick A. Ott et al.
NATURE (2017)
The immune contexture in cancer prognosis and treatment
Wolf H. Fridman et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
High TGF-β1 expression predicts poor disease prognosis in hepatocellular carcinoma patients
Li Peng et al.
ONCOTARGET (2017)
Anti-GPEC3-CAR T Cells Suppress the Growth of Tumor Cells in Patient-Derived Xenogratfts of Hepatocelluar Carcinoma
Zhiwu Jiang et al.
FRONTIERS IN IMMUNOLOGY (2017)
Neoantigens Generated by Individual Mutations and Their Role in Cancer Immunity and Immunotherapy
Mirjana Efremova et al.
FRONTIERS IN IMMUNOLOGY (2017)
Cytokines for the induction of antitumor effectors: The paradigm of Cytokine-Induced Killer (CIK) cells
Elisa Cappuzzello et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2017)
Liver macrophages in tissue homeostasis and disease
Oliver Krenkel et al.
NATURE REVIEWS IMMUNOLOGY (2017)
Targeting neoantigens to augment antitumour immunity
Mark Yarchoan et al.
NATURE REVIEWS CANCER (2017)
Applications of Immunogenomics to Cancer
X. Shirley Liu et al.
CELL (2017)
Immunogenic cell death in cancer and infectious disease
Lorenzo Galluzzi et al.
NATURE REVIEWS IMMUNOLOGY (2017)
Developments in cancer vaccines for hepatocellular carcinoma
Luigi Buonaguro
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
Engineered cytotoxic T lymphocytes with AFP-specific TCR gene for adoptive immunotherapy in hepatocellular carcinoma
Longhao Sun et al.
TUMOR BIOLOGY (2016)
Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells
Alfonso R. Sanchez-Paulete et al.
CANCER DISCOVERY (2016)
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
Weiyi Peng et al.
CANCER DISCOVERY (2016)
Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX-Bevacizumab Drug Treatment Regimen
Emeric Limagne et al.
CANCER RESEARCH (2016)
Management of toxicities of immune checkpoint inhibitors
Lavinia Spain et al.
CANCER TREATMENT REVIEWS (2016)
Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib
Shao-Lai Zhou et al.
GASTROENTEROLOGY (2016)
Programmed Death Ligand 1 Expression in Hepatocellular Carcinoma: Relationship With Clinical and Pathological Features
Julien Calderaro et al.
HEPATOLOGY (2016)
Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial
Riccardo Lencioni et al.
JOURNAL OF HEPATOLOGY (2016)
Overexpression of CD39 in hepatocellular carcinoma is an independent indicator of poor outcome after radical resection
Xiao-Yan Cai et al.
MEDICINE (2016)
Immune checkpoint proteins PD-1 and TIM-3 are both highly expressed in liver tissues and correlate with their gene polymorphisms in patients with HBV-related hepatocellular carcinoma
Zhu Li et al.
MEDICINE (2016)
Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer
Akihiro Fujimoto et al.
NATURE GENETICS (2016)
Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges
Emilie M. J. van Brummelen et al.
ONCOLOGIST (2016)
Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma
Stefani Spranger et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
PD-1hi Identifies a Novel Regulatory B-cell Population in Human Hepatoma That Promotes Disease Progression
Xiao Xiao et al.
CANCER DISCOVERY (2016)
TGF-β induces M2-like macrophage polarization via SNAIL-mediated suppression of a pro-inflammatory phenotype
Fan Zhang et al.
ONCOTARGET (2016)
Natural killer cells phenotypic characterization as an outcome predictor of HCV-linked HCC after curative treatments
Elisabetta Cariani et al.
ONCOIMMUNOLOGY (2016)
Hepatocellular carcinoma
Josep M. Llovet et al.
NATURE REVIEWS DISEASE PRIMERS (2016)
TGF-β and VEGF cooperatively control the immunotolerant tumor environment and the efficacy of cancer immunotherapies
Tristan Courau et al.
JCI INSIGHT (2016)
Tumor-infiltrating lymphocyte activity is enhanced in tumors with low IL-10 production in HBV-induced hepatocellular carcinoma
Yang Shi et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2015)
High Serum Transforming Growth Factor-β1 Levels Predict Outcome in Hepatocellular Carcinoma Patients Treated with Sorafenib
Tzu-Hsuan Lin et al.
CLINICAL CANCER RESEARCH (2015)
Tim-3 fosters HCC development by enhancing TGF-β-mediated alternative activation of macrophages
Wenjiang Yan et al.
GUT (2015)
Hepatic stellate cell and monocyte interaction contributes to poor prognosis in hepatocellular carcinoma
Juling Ji et al.
HEPATOLOGY (2015)
Alternatively activated (M2) macrophages promote tumour growth and invasiveness in hepatocellular carcinoma
Oscar W. H. Yeung et al.
JOURNAL OF HEPATOLOGY (2015)
The yin and yang of evasion and immune activation in HCC
Oxana V. Makarova-Rusher et al.
JOURNAL OF HEPATOLOGY (2015)
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
Jordi Bruix et al.
LANCET ONCOLOGY (2015)
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Stefani Spranger et al.
NATURE (2015)
Immunological landscape and immunotherapy of hepatocellular carcinoma
Jesus Prieto et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2015)
Adoptive cell transfer as personalized immunotherapy for human cancer
Steven A. Rosenberg et al.
SCIENCE (2015)
Neoantigens in cancer immunotherapy
Ton N. Schumacher et al.
SCIENCE (2015)
A phase I clinical trial utilizing autologous tumor-infiltrating lymphocytes in patients with primary hepatocellular carcinoma
Shan-Shan Jiang et al.
ONCOTARGET (2015)
Serum Interleukin-8 Reflects Tumor Burden and Treatment Response across Malignancies of Multiple Tissue Origins
Miguel F. Sanmamed et al.
CLINICAL CANCER RESEARCH (2014)
Development of T Cells Redirected to Glypican-3 for the Treatment of Hepatocellular Carcinoma
Huiping Gao et al.
CLINICAL CANCER RESEARCH (2014)
Enhanced suppressor function of TIM-3+FoxP3+ regulatory T cells
Anne-Sophie Gautron et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2014)
Human CD14+CTLA-4+ Regulatory Dendritic Cells Suppress T-Cell Response by Cytotoxic T-Lymphocyte Antigen-4-Dependent IL-10 and Indoleamine-2,3-Dioxygenase Production in Hepatocellular Carcinoma
Yanmei Han et al.
HEPATOLOGY (2014)
Brivanib as Adjuvant Therapy to Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma: A Randomized Phase III Trial
Masatoshi Kudo et al.
HEPATOLOGY (2014)
Immunodominance and Functional Alterations of Tumor-Associated Antigen-Specific CD8+ T-Cell Responses in Hepatocellular Carcinoma
Tobias Flecken et al.
HEPATOLOGY (2014)
Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib
Maria Reig et al.
JOURNAL OF HEPATOLOGY (2014)
Tumor-Derived α-Fetoprotein Impairs the Differentiation and T Cell Stimulatory Activity of Human Dendritic Cells
Angela D. Pardee et al.
JOURNAL OF IMMUNOLOGY (2014)
Human and Mouse VEGFA-Amplified Hepatocellular Carcinomas Are Highly Sensitive to Sorafenib Treatment
Elad Horwitz et al.
CANCER DISCOVERY (2014)
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy
Pierre G. Coulie et al.
NATURE REVIEWS CANCER (2014)
Increase in CD14+HLA-DR-/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis
Fumitaka Arihara et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
HLA and Killer Immunoglobulin-like Receptor Genes as Outcome Predictors of Hepatitis C Virus-Related Hepatocellular Carcinoma
Elisabetta Cariani et al.
CLINICAL CANCER RESEARCH (2013)
HLA ligandome tumor antigen discovery for personalized vaccine approach
Hans-Georg Rammensee et al.
EXPERT REVIEW OF VACCINES (2013)
Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma
Eishiro Mizukoshi et al.
HEPATOLOGY (2013)
Pituitary homeobox 2 (PITX2) protects renal cancer cell lines against doxorubicin toxicity by transcriptional activation of the multidrug transporter ABCB1
Wing-Kee Lee et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Interferon-dependent IL-10 production by Tregs limits tumor Th17 inflammation
C. Andrew Stewart et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
Bruno Sangro et al.
JOURNAL OF HEPATOLOGY (2013)
The functional impairment of HCC-infiltrating γδ T cells, partially mediated by regulatory T cells in a TGFβ- and IL-10-dependent manner
Yong Yi et al.
JOURNAL OF HEPATOLOGY (2013)
Activated human hepatic stellate cells induce myeloid derived suppressor cells from peripheral blood monocytes in a CD44-dependent fashion
Bastian Hoechst et al.
JOURNAL OF HEPATOLOGY (2013)
Hepatic Stellate Cells Preferentially Induce Foxp3+ Regulatory T Cells by Production of Retinoic Acid
Richard M. Dunham et al.
JOURNAL OF IMMUNOLOGY (2013)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
Improved affinity AFP-specific T cell receptor for hepatocellular carcinoma
Andrew B Gerry et al.
Journal for ImmunoTherapy of Cancer (2013)
Molecular mechanisms of T cell co-stimulation and co-inhibition
Lieping Chen et al.
NATURE REVIEWS IMMUNOLOGY (2013)
Phase I Trial of a Glypican-3-Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival
Yu Sawada et al.
CLINICAL CANCER RESEARCH (2012)
Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma
Hang Li et al.
HEPATOLOGY (2012)
Reduced NKG2D ligand expression in hepatocellular carcinoma correlates with early recurrence
Hiroteru Kamimura et al.
JOURNAL OF HEPATOLOGY (2012)
Human CCR4+CCR6+Th17 Cells Suppress Autologous CD8+ T Cell Responses
Fei Zhao et al.
JOURNAL OF IMMUNOLOGY (2012)
Efficacy, Safety, and Biomarkers of Single- Agent Bevacizumab Therapy in Patients with Advanced Hepatocellular Carcinoma
Valerie Boige et al.
ONCOLOGIST (2012)
Dendritic Cell-Based Vaccines Positively Impact Natural Killer and Regulatory T Cells in Hepatocellular Carcinoma Patients
Sarah M. Bray et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2011)
Cross-Presentation of Antigen by Diverse Subsets of Murine Liver Cells
Mohammad R. Ebrahimkhani et al.
HEPATOLOGY (2011)
PD-1 and PD-L1 upregulation promotes CD8+ T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients
Feng Shi et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Selective Recruitment of Regulatory T Cell through CCR6-CCL20 in Hepatocellular Carcinoma Fosters Tumor Progression and Predicts Poor Prognosis
Kang-Jie Chen et al.
PLOS ONE (2011)
Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
Robert D. Schreiber et al.
SCIENCE (2011)
A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma
Tim F. Greten et al.
BMC CANCER (2010)
Safety of Bevacizumab in Patients with Advanced Cancer: A Meta-Analysis of Randomized Controlled Trials
Sabine Geiger-Gritsch et al.
ONCOLOGIST (2010)
Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity
Nitya Jain et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
The Liver as a Lymphoid Organ
Ian Nicholas Crispe
ANNUAL REVIEW OF IMMUNOLOGY (2009)
Kupffer Cell Suppression of CD8+ T Cells in Human Hepatocellular Carcinoma Is Mediated by B7-H1/Programmed Death-1 Interactions
Ke Wu et al.
CANCER RESEARCH (2009)
Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma
Qiang Gao et al.
CLINICAL CANCER RESEARCH (2009)
Myeloid Derived Suppressor Cells Inhibit Natural Killer Cells in Patients with Hepatocellular Carcinoma via the NKp30 Receptor
Bastian Hoechst et al.
HEPATOLOGY (2009)
Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients
Jia Zhou et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1
Dong-Ming Kuang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats
Thomas Reiberger et al.
JOURNAL OF HEPATOLOGY (2009)
A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4+CD25+Foxp3+ T cells
Bastian Hoechst et al.
GASTROENTEROLOGY (2008)
Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma
Abby B. Siegel et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Induction of immunosuppressive molecules and regulatory T cells counteracts the antitumor effect of interleukin-12-based gene therapy in a transgenic mouse model of liver cancer
Maider Zabala et al.
JOURNAL OF HEPATOLOGY (2007)
Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection
Qiang Gao et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients
Junliang Fu et al.
GASTROENTEROLOGY (2007)
A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four α-fetoprotein peptides
LH Butterfield et al.
CLINICAL CANCER RESEARCH (2006)
TGF-β1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells
M Ahmadzadeh et al.
JOURNAL OF IMMUNOLOGY (2005)
Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma
LA Ormandy et al.
CANCER RESEARCH (2005)
A small molecule-kinase interaction map for clinical kinase inhibitors
MA Fabian et al.
NATURE BIOTECHNOLOGY (2005)
Possible contribution of circulating transforming growth factor-β1 to immunity and prognosis in unresectable hepatocellular carcinoma
K Okumoto et al.
LIVER INTERNATIONAL (2004)
Immunoregulation of dendritic and T cells by alpha-fetoprotein in patients with hepatocellular carcinoma
M Ritter et al.
JOURNAL OF HEPATOLOGY (2004)
The danger model: A renewed sense of self
P Matzinger
SCIENCE (2002)
A role for TGF-β in the generation and expansion of CD4+CD25+ regulatory T cells from human peripheral blood
S Yamagiwa et al.
JOURNAL OF IMMUNOLOGY (2001)
PD-L2 is a second ligand for PD-I and inhibits T cell activation
Y Latchman et al.
NATURE IMMUNOLOGY (2001)
Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial
T Takayama et al.
LANCET (2000)
The impact of interferon gamma receptor expression on the mechanism of escape from host immune surveillance in hepatocellular carcinoma
M Nagao et al.
HEPATOLOGY (2000)
分享论文
